Short Interest in Genprex, Inc. (NASDAQ:GNPX) Drops By 47.3%

Genprex, Inc. (NASDAQ:GNPX) was the recipient of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 333,600 shares, a decrease of 47.3% from the February 28th total of 633,100 shares. Currently, 4.0% of the shares of the stock are short sold. Based on an average trading volume of 1,830,000 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Genprex stock. Virtu Financial LLC boosted its position in Genprex, Inc. (NASDAQ:GNPX) by 64.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 80,424 shares of the company’s stock after purchasing an additional 31,400 shares during the period. Virtu Financial LLC owned about 0.95% of Genprex worth $68,000 as of its most recent SEC filing. 14.05% of the stock is owned by institutional investors and hedge funds.

Genprex Price Performance

Genprex stock traded down $0.07 during midday trading on Friday, reaching $0.27. The company’s stock had a trading volume of 3,612,556 shares, compared to its average volume of 3,047,860. Genprex has a fifty-two week low of $0.25 and a fifty-two week high of $4.09. The stock’s 50 day simple moving average is $0.45 and its 200 day simple moving average is $0.81.

About Genprex

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.